- Price
- $12.56
- Day
- +6.35%
- Mkt Cap
- $856.40M
- 52W Range
- $1.54 – $14.42
- Volume
- 912.2K
- Beta
- 0.07
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report)'s stock price reached a new 52-week high during trading on Tuesday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the stock. Climb Bio traded as high as $14.42 and last traded at $12.79, with a
Read full article
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) shot up 10.9% on Monday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the stock. Climb Bio traded as high as $14.25 and last traded at $14.24. Approximately 228,260 shares changed hands during trading, a
Read full article
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility
Read full article